Stock of The Day: Eiger Biopharmaceuticals Inc Can’t Burn Your Short Portfolio. Just Reaches All-Time Low

Stock of The Day: Eiger Biopharmaceuticals Inc Can't Burn Your Short Portfolio. Just Reaches All Time Low

The stock of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) reached all time low today, Oct, 13 and still has $10.99 target or 11.00% below today’s $12.35 share price. This indicates more downside for the $100.91M company. This technical setup was reported by If the $10.99 PT is reached, the company will be worth $11.10 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 27,944 shares traded hands. Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has declined 17.41% since March 10, 2016 and is downtrending. It has underperformed by 24.93% the S&P500.

Analysts await Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) to report earnings on November, 14. They expect $-1.17 EPS, up 71.11% or $2.88 from last year’s $-4.05 per share. After $-1.87 actual EPS reported by Eiger Biopharmaceuticals Inc for the previous quarter, Wall Street now forecasts -37.43% EPS growth.

According to Zacks Investment Research, “Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.”

More notable recent Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) news were published by: which released: “/quotes/zigman/3870025/realtime” on March 24, 2016, also with their article: “Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock” published on August 17, 2016, published: “Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the …” on September 06, 2016. More interesting news about Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) were released by: and their article: “Eiger BioPharmaceuticals to Present at the 2016 Wedbush PacGrow Healthcare …” published on August 08, 2016 as well as‘s news article titled: “Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY …” with publication date: July 18, 2016.

EIGR Company Profile

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, incorporated on February 24, 2012, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of products for the treatment of orphan diseases. The Company’s pipeline includes three Phase II candidates addressing over four distinct orphan diseases. The Company’s pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment